Investment Analysts’ Weekly Ratings Updates for Editas Medicine (EDIT)
A number of firms have modified their ratings and price targets on shares of Editas Medicine (NASDAQ: EDIT) recently: 3/1/2024 – Editas Medicine was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating. 2/29/2024 – Editas Medicine had its price target raised by analysts at Barclays PLC from $10.00 to $11.00. […]
More Stories
iShares Short Duration Bond Active ETF (BATS:NEAR) Hits New 1-Year High – What’s Next?
iShares Short Duration Bond Active ETF (BATS:NEAR – Get Free Report) hit a new 52-week high on Monday . The...
Nuveen ESG Large-Cap Growth ETF (BATS:NULG) Reaches New 1-Year High – Should You Buy?
Nuveen ESG Large-Cap Growth ETF (BATS:NULG – Get Free Report) reached a new 52-week high during trading on Monday ....
Scout24 (ETR:G24) Sets New 52-Week High – Here’s Why
Scout24 SE (ETR:G24 – Get Free Report) shares hit a new 52-week high during trading on Monday . The company...
iShares MSCI USA Value Factor ETF (BATS:VLUE) Hits New 12-Month High – Time to Buy?
iShares MSCI USA Value Factor ETF (BATS:VLUE – Get Free Report)’s share price hit a new 52-week high during mid-day...
iShares MSCI Chile ETF (BATS:ECH) Reaches New 12-Month Low – Time to Sell?
iShares MSCI Chile ETF (BATS:ECH – Get Free Report)’s stock price reached a new 52-week low during mid-day trading on...
Wacker Chemie (ETR:WCH) Sets New 12-Month Low – Should You Sell?
Wacker Chemie AG (ETR:WCH – Get Free Report)’s share price hit a new 52-week low on Monday . The stock...